Introduction {#S0001}
============

Approximately 5.3 million Japanese adults over the age of 40 have airflow limitation indicative of COPD; however, it is estimated that more than 5 million of these patients are not currently receiving treatment intervention.[@CIT0001] Effective treatment of COPD can improve lung function, decrease symptoms, and prevent exacerbations, and typically includes bronchodilators (long-acting muscarinic antagonists \[LAMAs\] and/or long-acting β~2~-agonists \[LABAs\]) alone or in combination with an inhaled corticosteroid (ICS).[@CIT0002] For symptomatic patients with moderate-to-very severe COPD, with or without a history of exacerbations, several Phase III studies have demonstrated the benefits of triple ICS/LAMA/LABA combinations compared with dual LAMA/LABA and ICS/LABA therapies on lung function, symptoms, and COPD exacerbations.[@CIT0003]--[@CIT0006] Nevertheless, it is important to consider the long-term safety of these treatments to determine their overall risk/benefit profile, as the prolonged use of ICS in COPD has been associated with the potential for adverse events (AEs), including pneumonia and cataracts.[@CIT0002]

To date, three triple fixed-dose combination ICS/LAMA/LABA therapies have been developed,[@CIT0007] including budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI), which is formulated using co-suspension delivery technology.[@CIT0008] The efficacy and safety of BGF MDI were assessed in the pivotal Phase III KRONOS study, which found that triple therapy had benefits on lung function, symptoms, and exacerbations versus dual therapy with glycopyrrolate/formoterol fumarate (GFF) MDI or budesonide/formoterol fumarate (BFF) MDI.[@CIT0003] In addition, the safety profile of BGF MDI was comparable to that of both dual therapies. However, as ethnic and regional factors can result in differences in drug response,[@CIT0009] it is important to assess the long-term safety and efficacy of these therapies in a variety of populations. KRONOS included 416 patients enrolled in Japan, and efficacy and safety findings in the Japanese subgroup were generally comparable to the overall population.[@CIT0010] To further characterize the risk/benefit profile of triple therapy in Japanese patients, we evaluated the long-term safety and efficacy of BGF MDI over 52 weeks in patients from Japan with moderate-to-very severe COPD who participated in a 28-week extension of the 24-week KRONOS study.

Materials and Methods {#S0002}
=====================

Study Design {#S0002-S2001}
------------

KRONOS (NCT02497001) was a Phase III, double-blind, multicenter parallel-group study in which patients were randomized 2:2:1:1 to receive BGF MDI 320/18/9.6 μg, GFF MDI 18/9.6 μg, BFF MDI 320/9.6 μg, or open-label budesonide/formoterol dry powder inhaler (BUD/FORM DPI; Symbicort Turbuhaler^®^) 400/12 μg, twice-daily for 24 weeks.[@CIT0003] The doses of glycopyrrolate and formoterol fumarate (18 μg and 9.6 μg, respectively) are equivalent to 14.4 µg glycopyrronium and 10 µg formoterol fumarate dihydrate. BUD/FORM DPI 400/12 μg was administered as two inhalations of 200/6 μg (metered dose, corresponding to a total daily delivered dose of 320/9 μg). During the extension study (NCT03262012), Japanese patients receiving BGF MDI, GFF MDI, BFF MDI, or BUD/FORM DPI in KRONOS continued their randomized treatment for up to 28 additional weeks, resulting in a total of 52 weeks' treatment ([Figure 1](#F0001){ref-type="fig"}).Figure 1Study design.**Notes:** \*Visits 10a and 10b were conducted on the same day. Visit 10b began immediately following completion of Visit 10a procedures.**Abbreviations:** BFF, budesonide/formoterol fumarate; BGF, budesonide/glycopyrrolate/formoterol fumarate; BUD/FORM DPI, budesonide/formoterol fumarate dry powder inhaler; GFF, glycopyrrolate/formoterol fumarate; MDI, metered dose inhaler.

The study was conducted in accordance with Good Clinical Practice, including the Declaration of Helsinki. The protocol and informed consent form were approved by appropriate institutional review boards (full details have been published).[@CIT0003] All patients provided written informed consent before screening.

Patients {#S0002-S2002}
--------

Full inclusion/exclusion criteria for KRONOS have been published previously,[@CIT0003] and these criteria also applied to the extension study. Briefly, requirements for study entry in KRONOS included an established clinical history of COPD (defined for patients in Japan using Japanese Respiratory Society guidelines[@CIT0011]), a smoking history of ≥10 pack-years, a COPD Assessment Test (CAT) score ≥10 despite receiving two or more inhaled maintenance therapies for at least 6 weeks before screening, and a post-bronchodilator forced expiratory volume in 1 s (FEV~1~) ≥25% and \<80%, according to predicted normal values using reference norms for Japan.[@CIT0011],[@CIT0012] There was no requirement for a history of COPD exacerbations in the year prior to study entry. Patients with a current diagnosis of asthma were excluded. In addition, for inclusion in the 28-week extension study, patients had to give informed consent to participate, and complete the treatment phase of KRONOS compliant with study procedures and study drug dosing.

Assessments {#S0002-S2003}
-----------

The primary objective was to evaluate the long-term safety and tolerability of BGF MDI, GFF MDI, BFF MDI, and BUD/FORM DPI in Japanese patients with moderate-to-very severe COPD. Safety assessments included AE monitoring, 12-lead electrocardiograms, clinical laboratory testing, and vital sign measurements. AEs of special interest (AESIs) included pneumonia, paradoxical bronchospasm, and several classes of AEs identified based on pharmacologically predictable effects, including: cardiovascular effects, ocular disorders, urinary retention, gastrointestinal disorders, and anticholinergic effects (LAMAs); cardiovascular effects, tremor, hyperglycemia, and hypokalemia (LABAs); and local (e.g., candidiasis and voice effects) and systemic (e.g., bone and skin effects, diabetes control, ocular and taste effects, adrenal suppression) steroid class effects, and lung infection (ICS). The relationship of AEs to the study treatment was assessed by the investigators after careful consideration, and according to the guidelines outlined in the [[Supplementary Materials](https://www.dovepress.com/get_supplementary_file.php?f=220861.docx)]{.ul}.

An external clinical endpoint committee (CEC) that was initiated in KRONOS continued to adjudicate pneumonia, major adverse cardiovascular events (MACE), and causes of death for the extension phase of the study to ensure appropriate pre-defined and clinically consistent criteria were met. An external data monitoring committee monitored the safety data at predetermined intervals.

Efficacy assessments included change from baseline in morning pre-dose trough FEV~1~ over 52 weeks, rate of moderate or severe COPD exacerbations (as defined in KRONOS[@CIT0003]), change from baseline in average daily rescue medication use, and change from baseline in the Evaluating Respiratory Symptoms (E-RS) in COPD total score, as well as three subscale scores (breathlessness, cough and sputum, and chest symptoms) over 52 weeks. Baseline assessments were conducted as part of enrollment in the KRONOS study, either during screening (for rescue medication use and E-RS scores) or at randomization (for FEV~1~).

Statistical Analysis {#S0002-S2004}
--------------------

A sample size of 324 Japanese patients from KRONOS (BGF MDI, n=108; GFF MDI, n=108; BFF MDI, n=54: BUD/FORM DPI, n=54) was selected to provide approximately 100 completing patients in the BGF MDI and GFF MDI arms. The Japanese safety and modified intent-to-treat (mITT) populations were subgroups of the global KRONOS safety and mITT populations that included the patients enrolled at sites in Japan, regardless of participation in the extension study. Patients who did not receive any study drug were excluded from the Japanese safety population. Hypothesis testing was not performed for any safety analyses. Variables were summarized with descriptive statistics, frequency counts, and percentages, as appropriate.

Efficacy assessments were considered to be exploratory as the primary purpose of the extension study was to assess safety. For the efficacy assessments, the estimand of interest was the efficacy estimand (the effect of the randomized treatment assuming continuation of randomized treatments for the duration of the study, regardless of actual adherence to study medication), for which analyses were conducted in the Japanese mITT population, using data obtained prior to patients discontinuing from treatment. The change from baseline in morning pre-dose trough FEV~1~ over 52 weeks was analyzed using a repeated measures linear mixed model including treatment, visit, treatment-by-visit interaction, ICS use at screening, baseline trough FEV~1~, baseline eosinophil count, and percent reversibility to albuterol. Rate of moderate or severe COPD exacerbations, change from baseline in average daily rescue medication use, and change from baseline in E-RS scores were summarized descriptively.

Results {#S0003}
=======

Study Population {#S0003-S2001}
----------------

A total of 416 Japanese patients were randomized and treated in KRONOS (21.9% of the global study population; [Figure 2](#F0002){ref-type="fig"}). These patients were included in the Japanese KRONOS safety and mITT populations. Of these, 377 patients (90.6%) completed 24 weeks of treatment in KRONOS and were eligible to continue in the extension study, and 347 patients (83.4%) consented to participate and were treated for up to an additional 28 weeks. Full demographic characteristics of the Japanese safety population have been published.[@CIT0010] In brief, the majority of Japanese patients were male (94.2%) with a mean age of 69.5 years. Eighty percent of patients had not experienced a COPD exacerbation in the previous year, and only 31.5% were receiving an ICS at study entry. In general, demographics were balanced across treatment groups in the Japanese population; however, the proportion of patients who had experienced at least one exacerbation in the previous year was larger in the BGF MDI group (25.9%) compared to the dual therapy groups (range: 15.9--17.4%). The median study drug exposure was 364.0 days in all four treatment groups; overall, 79.1% of patients had ≥48 weeks of exposure.Figure 2Patient disposition.**Notes:** ^a^All 416 Japanese patients who were randomized and treated in KRONOS were included in the Japanese mITT and safety populations, regardless of participation in the extension study.**Abbreviations:** BFF, budesonide/formoterol fumarate; BGF, budesonide/glycopyrrolate/formoterol fumarate; BUD/FORM DPI, budesonide/formoterol fumarate dry powder inhaler; GFF, glycopyrrolate/formoterol fumarate; MDI, metered dose inhaler; mITT, modified intent-to-treat.

Safety {#S0003-S2002}
------

Over 52 weeks, the majority of patients (82.7%) experienced at least 1 treatment-emergent AE (TEAE); most were mild or moderate in intensity and were not considered by the investigator to be treatment-related ([Table 1](#T0001){ref-type="table"}). The incidence of TEAEs considered related to study treatment was similar in the BGF MDI and BFF MDI groups (24.5% and 22.9%, respectively) and lower in the GFF MDI and BUD/FORM DPI groups (11.6% and 13.0%, respectively; [Table 1](#T0001){ref-type="table"}). The incidence of serious TEAEs ranged from 15.1% to 21.7% across treatment groups and was highest in the GFF MDI group ([Table 1](#T0001){ref-type="table"}). The most commonly reported TEAEs overall were nasopharyngitis (32.2%), bronchitis (9.9%), and muscle spasms (7.5%; [Table 2](#T0002){ref-type="table"}). In general, the profile and frequency of TEAEs were similar across treatment groups. Dysphonia and candidiasis, pharmacologically expected local steroid effects, occurred more frequently in the three ICS-containing treatment groups. Among the preferred terms identified as AESIs, only bronchitis, pneumonia, dysphonia, and candidiasis occurred in ≥3% of patients in any treatment group ([Table 2](#T0002){ref-type="table"}).Table 1Summary of Adverse Events (Japanese Safety Population)TEAEs, n (%)BGF MDI 320/18/9.6 µg N=139GFF MDI 18/9.6 µg N=138BFF MDI 320/9.6 µg N=70BUD/FORM DPI 400/12 µg N=69Patients with ≥1 TEAE115 (82.7)114 (82.6)58 (82.9)57 (82.6) Mild66 (47.5)60 (43.5)36 (51.4)31 (44.9) Moderate34 (24.5)33 (23.9)17 (24.3)17 (24.6) Severe15 (10.8)21 (15.2)5 (7.1)9 (13.0)Patients with TEAEs related^a^ to study treatment34 (24.5)16 (11.6)16 (22.9)9 (13.0)Patients with TEAEs that led to early discontinuation10 (7.2)12 (8.7)4 (5.7)6 (8.7)Patients with serious TEAEs21 (15.1)30 (21.7)11 (15.7)14 (20.3)Patients with serious TEAEs related^a^ to study treatment3 (2.2)7 (5.1)2 (2.9)3 (4.3)Patients with confirmed^b^ MACE1 (0.7)1 (0.7)02 (2.9)Patients with confirmed^b^ pneumonia13 (9.4)5 (3.6)4 (5.7)2 (2.9) At or before 24 weeks7 (5.0)1 (0.7)00 During weeks 25--526 (4.3)4 (2.9)4 (5.7)2 (2.9)Deaths (all causes)3 (2.2)1 (0.7)1 (1.4)1 (1.4)[^1][^2] Table 2Adverse Events Occurring in ≥3% of Patients in Any Treatment Group (Japanese Safety Population)Preferred Term, n (%)BGF MDI 320/18/9.6 µg N=139GFF MDI 18/9.6 µg N=138BFF MDI 320/9.6 µg N=70BUD/FORM DPI 400/12 µg N=69Nasopharyngitis45 (32.4)43 (31.2)22 (31.4)24 (34.8)Bronchitis15 (10.8)11 (8.0)8 (11.4)7 (10.1)Muscle spasms16 (11.5)6 (4.3)6 (8.6)3 (4.3)Pneumonia^a^14 (10.1)5 (3.6)4 (5.7)4 (5.8)Dysphonia10 (7.2)1 (0.7)9 (12.9)3 (4.3)COPD^b^7 (5.0)11 (8.0)2 (2.9)2 (2.9)Upper respiratory tract infection10 (7.2)8 (5.8)1 (1.4)2 (2.9)Influenza5 (3.6)7 (5.1)3 (4.3)6 (8.7)Upper respiratory tract inflammation5 (3.6)7 (5.1)5 (7.1)0Constipation6 (4.3)5 (3.6)4 (5.7)2 (2.9)Pharyngitis3 (2.2)5 (3.6)3 (4.3)2 (2.9)Eczema1 (0.7)3 (2.2)4 (5.7)4 (5.8)Oral candidiasis5 (3.6)03 (4.3)3 (4.3)Pyrexia3 (2.2)6 (4.3)00Oropharyngeal pain5 (3.6)1 (0.7)1 (1.4)1 (1.4)Contusion5 (3.6)1 (0.7)01 (1.4)[^3][^4]

To evaluate the association between treatment exposure and TEAE incidence, we assessed TEAEs over time across 12-week intervals. Although the incidence of individual TEAEs fluctuated within and across treatment groups over time, there was no evidence that the frequency of individual TEAEs increased based on the duration of exposure ([Table 3](#T0003){ref-type="table"}).Table 3Summary of Adverse Events by Time Period (Japanese Safety Population)Patients with TEAEs, n (%)Weeks 0--12Weeks 13--24Weeks 25--36Weeks 37--52BGF MDI N=139GFF MDI N=138BFF MDI N=70BUD/FORM DPI N=69BGF MDI N=134GFF MDI N=124BFF MDI N=65BUD/ FORM DPI N=65BGF MDI N=118GFF MDI N=113BFF MDI N=59BUD/ FORM DPI N=62BGF MDI N=114GFF MDI N=107BFF MDI N=58BUD/ FORM DPI N=58≥1 TEAE78 (56.1)62 (44.9)38 (54.3)28 (40.6)59 (44.0)48 (38.7)31 (47.7)25 (38.5)49 (41.5)48 (42.5)21 (35.6)26 (41.9)54 (47.4)55 (51.4)27 (46.6)28 (48.3)TEAEs related^a^ to study treatment21 (15.1)7 (5.1)10 (14.3)4 (5.8)11 (8.2)4 (3.2)5 (7.7)05 (4.2)4 (3.5)5 (8.5)4 (6.5)7 (6.1)1 (0.9)3 (5.2)2 (3.4)TEAEs leading to early discontinuation5 (3.6)3 (2.2)1 (1.4)2 (2.9)2 (1.5)3 (2.4)1 (1.5)02 (1.7)5 (4.4)01 (1.6)2 (1.8)1 (0.9)2 (3.4)3 (5.2)Serious TEAEs6 (4.3)7 (5.1)5 (7.1)4 (5.8)5 (3.7)10 (8.1)2 (3.1)2 (3.1)7 (5.9)12 (10.6)2 (3.4)5 (8.1)7 (6.1)8 (7.5)2 (3.4)5 (8.6)Serious TEAEs related^a^ to study treatment02 (1.4)001 (0.7)2 (1.6)001 (0.8)2 (1.8)1 (1.7)3 (4.8)1 (0.9)1 (0.9)1 (1.7)0Deaths (all causes)000001 (0.8)1 (1.5)02 (1.7)0001 (0.9)001 (1.7)[^5][^6]

Four patients experienced a CEC-confirmed MACE: one cardiovascular death in both the BGF MDI and GFF MDI groups, and two non-fatal myocardial infarctions in the BUD/FORM DPI group. None were considered by the investigator to be related to study treatment. The percentage of patients with CEC-confirmed pneumonia events ranged from 2.9% to 9.4% across the treatment groups, with the highest percentage in the BGF MDI group ([Table 1](#T0001){ref-type="table"}).

While the incidence of confirmed pneumonia during the first 24 weeks was highest in the BGF MDI group compared with the dual therapy groups, this pattern did not continue in the 28-week extension phase of the study. In the BGF MDI group, the incidence of confirmed pneumonia was similar in the first 24 weeks (5.0%) and after 24 weeks (4.3%), while in the other three treatment groups incidence was higher after 24 weeks (range: 2.9--5.7%) compared with the first 24 weeks (range: 0--0.7%; [Table 1](#T0001){ref-type="table"}). Overall, out of 24 confirmed pneumonia events, only five were considered possibly related to study treatment (n=2 in the BGF MDI and GFF MDI groups, and n=1 in the BUD/FORM DPI group).

Six deaths were reported during the study, none of which were considered to be treatment-related by the investigator. Three deaths occurred in the BGF MDI group (resulting from a traffic accident, pneumonia with disseminated intravascular coagulation, and lethal arrhythmia). The investigator considered the fatal pneumonia to be a complication of the anticancer treatment that the patient was receiving for colon cancer, and the death due to lethal arrhythmia occurred in a 73-year-old male who suffered a cardiopulmonary arrest after returning home from field work and died in hospital four days later. One death was reported in each of the GFF MDI, BFF MDI, and BUD/FORM DPI groups (resulting from cardio-respiratory arrest, squamous cell carcinoma, and lung adenocarcinoma, respectively).

No clinically meaningful trends were observed in electrocardiogram findings, laboratory parameters, or vital signs over time in any of the treatment groups.

Efficacy {#S0003-S2003}
--------

Treatment with BGF MDI resulted in a larger mean change from baseline in morning pre-dose trough FEV~1~ (least squares mean \[LSM\] 117 mL) compared with dual therapies (LSM range: 54−85 mL; [[Supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=220861.docx)]{.ul}), with the trend of greater improvements in the BGF MDI group maintained over the 52-week treatment period ([Figure 3](#F0003){ref-type="fig"}). At baseline, Japanese patients reported low use of rescue medication, ranging from 0.5 to 0.8 puffs of albuterol/day across treatment groups. Correspondingly, mean changes from baseline in daily rescue medication use over 52 weeks were also small and similar for all treatment groups (range: 0 to −0.3 puffs/day; [[Supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=220861.docx)]{.ul}). The percentage of patients experiencing a moderate or severe COPD exacerbation over 52 weeks ranged from 20.0% to 31.9% and was highest in the GFF MDI group ([[Supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=220861.docx)]{.ul}). Rates of moderate or severe exacerbations were comparable across the three ICS-containing treatments (range: 0.26--0.37 per year) and highest for GFF MDI (0.81 per year; [[Supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=220861.docx)]{.ul}). Changes from baseline in E-RS total score over 52 weeks ranged from −0.2 (GFF MDI) to −0.9 (BGF MDI; [[Supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=220861.docx)]{.ul}). Improvements in RS-breathlessness score were also greater for BGF MDI compared with dual therapies, while changes in RS-cough and sputum and RS-chest symptoms scores were similar across treatment groups ([[Supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=220861.docx)]{.ul}).Figure 3Change from baseline in morning pre-dose trough FEV~1~ over 52 weeks (efficacy estimand; Japanese mITT population).**Note:** Error bars represent the standard error.**Abbreviations:** BFF, budesonide/formoterol fumarate; BGF, budesonide/glycopyrrolate/formoterol fumarate; BUD/FORM DPI, budesonide/formoterol fumarate dry powder inhaler; FEV~1~, forced expiratory volume in 1 s; GFF, glycopyrrolate/formoterol fumarate; LSM, least squares mean; MDI, metered dose inhaler; mITT, modified intent-to-treat.

Discussion {#S0004}
==========

This 28-week extension study of the KRONOS trial assessed the long-term safety and efficacy of the ICS/LAMA/LABA triple therapy, BGF MDI, over 52 total weeks of treatment in Japanese patients with moderate-to-very severe COPD. BGF MDI was generally well tolerated in Japanese patients, with a safety profile broadly similar to that of the corresponding dual LAMA/LABA and ICS/LABA therapies.

Overall, the incidence of TEAEs was consistent across treatment groups (range: 82.6−82.9%), and the majority of reported TEAEs were of mild or moderate intensity. Although the frequency of individual TEAEs fluctuated within and across treatment groups over time, there was no evidence that the profile or frequency of individual TEAEs increased based on the duration of exposure, suggesting no cumulative adverse effects of treatment over time.

A previous history of moderate or severe exacerbations may be a risk factor for the development of pneumonia in patients with COPD.[@CIT0013] It should be noted that 25.9% of patients in the BGF MDI group had experienced an exacerbation in the year prior to enrollment, which was higher than in the dual therapy groups (range: 15.9--17.4%). In this regard, 5 of the 7 patients in the BGF MDI group with a confirmed pneumonia event in the first 24 weeks of the study had experienced an exacerbation in the year prior to study entry, whereas no patients in the other three treatment groups who developed pneumonia over the 52-week study reported a prior history of exacerbation. This could potentially account for the imbalance of pneumonia in the BGF MDI group in the first 24 weeks of the study, as no patients who developed pneumonia after 24 weeks had a risk factor of a prior exacerbation, and the incidence across groups was comparable in the second half of the study.

Over 52 weeks, pneumonia was confirmed in 2.9% to 9.4% of patients across the treatment groups, with the highest percentage in the BGF MDI group. However, only 2 of the 13 confirmed events in the BGF MDI group were considered by the investigator to be related to study treatment. As the incidence of pneumonia was lower in the BFF MDI and BUD/FORM DPI groups relative to the BGF MDI group, this finding does not appear to represent an effect of budesonide treatment. The number of patients with confirmed pneumonia was similar in the first 24 weeks (n=7) and after 24 weeks (n=6) in the BGF MDI group, indicating that pneumonia incidence did not increase with long-term use. In contrast, in the LAMA/LABA and ICS/LABA groups, the incidence of confirmed pneumonia was higher during the 28-week extension phase (range: 2.9−5.7%) compared with the first 24 weeks (range: 0−0.7%). Hence, the higher incidence of confirmed pneumonia in the BGF MDI group compared to the other treatment arms was primarily driven by events that occurred in the first 24 weeks of the study, and incidence was generally balanced across treatment groups after Week 24.

The overall incidence of confirmed pneumonia over 52 weeks was higher in Japanese patients (5.8%) compared with US patients (2.4%) who participated in a similar KRONOS extension study.[@CIT0014] Other multinational clinical studies in patients with COPD have also reported a higher incidence of pneumonia in Japanese and Asian patients relative to the full study population.[@CIT0015],[@CIT0016] This may be partly due to the older average age of the Japanese population (69.5 vs 62.8 years in the US extension study) and the higher frequency of diagnostic X-ray use in Japan versus the USA.[@CIT0017] Overall, these factors suggest that while the incidence of pneumonia was higher overall in Japanese patients compared to a previous 52-week study conducted in the USA,[@CIT0014] with the highest incidence observed in the BGF MDI group, these findings may have been influenced by regional effects and an imbalance in risk factors across treatment groups (e.g., prior exacerbation history), and were likely not treatment-related.

Overall, results for efficacy endpoints with BGF MDI were generally consistent with the findings in the Japanese and global populations of KRONOS,[@CIT0003],[@CIT0010] with greater improvement in lung function versus GFF MDI and BFF MDI, and reduction in symptoms and exacerbations versus GFF MDI. While efficacy analyses were considered exploratory due to the relatively small sample size of this safety extension study, the findings demonstrated that the treatment effects observed at 24 weeks[@CIT0010] were sustained over 52 weeks, and therefore support the long-term efficacy of BGF MDI.

Conclusions {#S0005}
===========

This 52-week study found that the safety profile of BGF MDI was generally comparable to dual LAMA/LABA and ICS/LABA therapies in Japanese patients with moderate-to-very severe COPD. All treatments were well tolerated, and there was no evidence that the profile or frequency of individual TEAEs differed based on the duration of exposure within or across treatment groups. Safety and efficacy results over 52 weeks were generally in agreement with findings from the global population and the Japanese subgroup of KRONOS over 24 weeks,[@CIT0003],[@CIT0010] and support the long-term tolerability of BGF MDI in Japanese patients with moderate-to-very severe COPD.
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[^3]: **Notes:** ^a^Spontaneously reported as AEs; not confirmed by clinical endpoint committee. ^b^Worsening of COPD.

[^4]: **Abbreviations:** AE, adverse event; BFF, budesonide/formoterol fumarate; BGF, budesonide/glycopyrrolate/formoterol fumarate; BUD/FORM DPI, budesonide/formoterol fumarate dry powder inhaler; GFF, glycopyrrolate/formoterol fumarate; MDI, metered dose inhaler.

[^5]: **Note:** ^a^Possibly, probably, or definitely related in the opinion of the investigator.

[^6]: **Abbreviations:** BFF, budesonide/formoterol fumarate; BGF, budesonide/glycopyrrolate/formoterol fumarate; BUD/FORM DPI, budesonide/formoterol fumarate dry powder inhaler; GFF, glycopyrrolate/formoterol fumarate; MDI, metered dose inhaler; TEAE, treatment-emergent adverse event.
